



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
18/883,719	09/12/2024	Atul Bedi	JHU3260-10	6410
100899	7590	12/23/2024	EXAMINER	
The John Hopkins University c/o DLA Piper LLP (US) 4365 Executive Drive, Suite 1100 San Diego, CA 92121-2133			BUNNER, BRIDGET E	
			ART UNIT	PAPER NUMBER
			1647	
			NOTIFICATION DATE	DELIVERY MODE
			12/23/2024	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gtdocket@dlapiper.com

<i>Applicant-Initiated Interview Summary</i>	Application No. 18/883,719	Applicant(s) Bedi et al.		
	Examiner BRIDGET E BUNNER	Art Unit 1647	AIA (First Inventor to File) Status No	Page 1 of 1

All Participants (applicant, applicants representative, PTO personnel)	Title	Type
BRIDGET E BUNNER	Primary Examiner	Video Conference
PAMELA HWANG	Attorney of Record	

Date of Interview: 17 December 2024

Issues Discussed:

Proposed Amendment(s)

Ms. Hwang discussed proposed amendments to claims 1 and 2 (as well as the addition of new dependent and independent claims) to address the claim objections and rejections set forth in the previous Office Action of 03 December 2024. Specifically, the proposed amendments would clarify the elements that comprise the claimed isolated molecule. Ms. Hwang also indicated the submission of a terminal disclaimer to address the nonstatutory double patenting rejections. The Examiner stated that such amendments (and terminal disclaimer submission) sounded reasonable to overcome the objections /rejections of record, but that such would be considered once officially made of record.

	/BRIDGET E BUNNER/ Primary Examiner, Art Unit 1647
<p>Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicants responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04</p> <p>Please further see: MPEP 713.04 Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b) 37 CFR § 1.2 Business to be transacted in writing</p>	

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.